Corient Private Wealth LP acquired a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 318,673 shares of the biotechnology company's stock, valued at approximately $2,667,000. Corient Private Wealth LP owned about 0.14% of ADMA Biologics at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently modified their holdings of the company. Summit Securities Group LLC bought a new position in ADMA Biologics during the fourth quarter worth about $29,000. Western Wealth Management LLC acquired a new position in ADMA Biologics during the first quarter worth approximately $31,000. iSAM Funds UK Ltd bought a new stake in ADMA Biologics in the third quarter valued at approximately $34,000. Morse Asset Management Inc bought a new stake in ADMA Biologics in the fourth quarter valued at approximately $44,000. Finally, EverSource Wealth Advisors LLC lifted its position in shares of ADMA Biologics by 385.8% in the second quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company's stock valued at $50,000 after buying an additional 2,180 shares during the last quarter. 75.68% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the company. Mizuho decreased their target price on ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating on the stock in a report on Wednesday, July 15th. Raymond James Financial began coverage on shares of ADMA Biologics in a research report on Wednesday, June 10th. They set an "outperform" rating and a $21.00 price objective for the company. Weiss Ratings reiterated a "hold (c)" rating on shares of ADMA Biologics in a report on Thursday, June 18th. Canaccord Genuity Group dropped their price objective on shares of ADMA Biologics from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, May 7th. Finally, Zacks Research cut shares of ADMA Biologics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, August 4th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, ADMA Biologics currently has a consensus rating of "Hold" and an average price target of $18.67.
Check Out Our Latest Report on ADMA
ADMA Biologics Price Performance
ADMA Biologics stock opened at $9.33 on Wednesday. ADMA Biologics Inc has a 12 month low of $7.21 and a 12 month high of $20.46. The stock's 50 day moving average is $9.10 and its 200-day moving average is $10.40. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of 13.33 and a beta of 0.78.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, hitting analysts' consensus estimates of $0.16. The company had revenue of $124.39 million for the quarter, compared to analyst estimates of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The firm's quarterly revenue was up 2.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.14 earnings per share. Equities research analysts expect that ADMA Biologics Inc will post 0.78 EPS for the current year.
About ADMA Biologics
(
Free Report)
ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.
The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.
Featured Articles
Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics Inc (NASDAQ:ADMA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider ADMA Biologics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.
While ADMA Biologics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
